Available Technologies


Project TitleNovel Prognostic Test for Outcome Prediction in Metastatic Colorectal Cancer
Track Code2016-115
Short Description
Tagscolorectal cancer, pharmacodiagnostics, diagnostics, biomarkers, oncology, precision medicine, personalized medicine
Posted DateAug 3, 2017 3:51 PM

Market Opportunity

Current first line treatments for metastatic colorectal cancer (mCRC) have improved overall patient survival time to 30 months, but few options remain if tumor progression continues. Diagnostic testing for biomarkers has emerged as a promising approach to tailor individualized treatments to improve clinical outcomes. However, even as the market for cancer pharmacodiagnostics is predicted to grow to $1 billion by 2021, only a few reliable biomarkers such as KRAS has been validated to distinguish therapeutic response to anti-EGFR drugs in mCRC patients.

USC Solution

USC researchers have discovered novel SNP biomarkers located in TLR genes that can predict patient outcomes of cetuximab or irinotecan-bevacizumab based chemotherapy in mCRC subtypes. These SNP biomarkers were discovered through meta-analysis of patient cohorts with wild type KRAS that responded positively to anti-EGFR drugs. Evaluation of these biomarkers are easily detected by PCR based diagnostics.

Value Proposition

  • Novel biomarkers for predicting response to cetuximab or irinotecan plus bevacizumab chemotherapy in metastatic colorectal cancer (mCRC) patients
  • High correlation of SNP genotype with improved patient outcomes 
  • Cost effective prognostic to determine suitable first line treatment of metastatic colorectal cancer


  • Methods to predict response to anti-EGFR chemotherapy in metastatic colorectal cancer

Stage of Development

  • Tested in clinical cohort studies
  • Available for exclusive or non-exclusive license

Intellectual Property

Contact Information

Camilo Ansarah-Sobrinho, Licensing Associate

USC Stevens Center for Innovation

(213) 821-6071



File Name Description
NCD 2016-115 - Novel Prognostic Test for Outcome Prediction in Metastatic Colorectal Cancer.pdf None Download